CTLA4 and cancer: Since the first FDA approval of anti-CTLA-4 (Ipilimumab) in 2011 [29], cancer immunotherapies are rapidly evolving, over half a dozen ICI therapies are already approved, and combinations are being extensively evaluated [49, 59].